Analysis of the EAP, page-40

I’ve been reading Left-e for some time now on the yahoo board. His deep understanding of biotech in general and his knowledge of what it takes for a therapy to be successful compared to many others make a huge difference when investing in Biotechs, especially for those like me who have only instinct to help them in such a complex field. When Mesoblast completed Rem-L phase 3, one of Left-e’s post convinced me that we were very close to a breakthrough and the more I understood the more I invested.

The above post is very typical of his style, 4 powerful points which I always find difficult to flag down. We may conclude with a “no further question your honor” as in a court! I particularly like the part regarding PIMS and Kawasaki. How can any other therapy be more eligible to children than Rem-L/ Ryoncil?!

So here we are Left-e I guess you’re now stuck with many of us here and the yahoo board Thank you Roy